SUPPORTING PAPER 1: BIBLIOGRAPHY

1.1. Wider literature (non-confidential)

1. "Health Impact of Predictable Long-Term Funding: Executive Summary" - 27 May 2009
2. "Lessons Learned: New Procurement Strategies for Vaccines", Final Report to the GAVI Board, 2002
3. Abt Associates Inc. (2004): "Evaluation of the first five years of GAVI Immunisation Services Support funding"
4. Abt Associates Inc. (2007): "Evaluation of the first five years of GAVI Immunisation Services Support funding"
5. Abt Associates Inc. (2008): "Evaluation of the GAVI Phase I Performance (2000–2005)"
6. Advance Market Commitment for Pneumococcal Vaccines (2010) "Annual Report 12 June 2009 – 31 March 2010", GAVI Secretariat
7. Advance Market Commitments for vaccines (2008): "Advance Market Commitment for Pneumococcal vaccines: Report of the monitoring and evaluability study"
8. Ales Bulir, Javier Hamann (2003): "Aid volatility: An empirical assessment", IMF Staff Papers, Vol. 50, No. 1
9. Alliance for Case Studies for Global Health (2009): "Case studies for global health: Building relationships. Sharing knowledge"
10. AMC (2010): "Annual report: 12 June 09 – 31 March 2010"
11. AMC website latest news (2010): "GSK vaccine receives AMC approval by Independent Assessment Committee", 7 May 2010
12. Amit Kumar, Jacob Puliyel (2007): "GAVI funding and assessment of vaccine cost-effectiveness", Lancet Correspondence, Vol 369 January 20, 2007
13. Ann Canavan, Jurrien Toonen, Riku Elovainio (2008): "Performance based financing: An international review of the literature", KIT Development Policy and Practice
14. Anna Triponel (2009): "GFATM: A new legal and conceptual framework for providing international development aid"
15. Anushua Sinha, Orin Levine, Maria D Knoll et al. (2007): "Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis", Lancet Vol. 369;389-96

16. B. Galichet, L. Goeman, P.S. Hill et al (2010): "Linking programmes and systems: Lessons from the GAVI Health System Strengthening window", Tropical Medicine and International Health, Vol. 15 No. 2 pp. 208-15 February 2010

17. Bill & Melinda Gates Foundation (2007): "New Vaccine Introduction Project"

18. Black RE, Morris SS, Bryce J. (2003): "Where and why are 10 million children dying every year?", Lancet 361: 2226–34.

19. Brooks A, Cutts FT, Justice J, Walt G. (1999): "Policy Study of Factors Influencing the Adoption of New and Underutilized Vaccines in Developing Countries", Children's Vaccine Initiative and USAID

20. Bruno Marchal, Anna Cavalli, Guy Kegels (2009): "Global health actors claim to support health system strengthening - Is this reality or rhetoric?", PLoS Medicine, April 2009, Vol.6, Issue 4

21. Burton A, Monasch R, Lautenbach B, Gacic-Dobo M, Neill M, Karimov R, Wolfson L, Jones G, Birmingham M. (2009) "WHO and UNICEF estimates of national immunization coverage: methods and processes", Bulletin of the World Health Organization 87:535–541.

22. C. Michaud, C.J.L. Murray (1994): "External assistance to the health sector in developing countries: a detailed analysis 1972-90", Bulletin of WHO, 72 (4): 639-651

23. Catherine Michaud (2003): "Development Assistance for Health (DAH): Recent trends and resource allocation", Paper presented for the Second Consultation Commission on Macroeconomics and Health, WHO, Geneva

24. Centre for Global Development Global Health Forecasting Working Group (2007) "A Risky Business: Saving money and improving global health through better demand forecasts"

25. Centre for Global Development: "HIV/AIDS Monitor - Concept Document"

26. Centre for Global Prosperity (2008): "The index of global philanthrophy"

27. Chee G, et al. (2008): "Evaluation of the GAVI Phase I Performance (2000–2005)", Bethesda, MD: Abt Associates Inc.

28. Chunling Lu et al (2010): "Public financing of health in developing countries: a cross-national systematic analysis", Lancet

29. Chunling Lu, Catherine M Michaud, Emmanuela Gakidou et al (2006): "Effect of the Global Alliance for Vaccines and Immunization on diptheria, tetanus and pertussis vaccine coverage: an independent assessment", Lancet; 368:1088-95

30. Danovaro-Holliday MC, Garcia S, de Qaudros C, Tambini G, Andrus JK (2008): "Progress in vaccination against Haemophilus influenzae type b in the Americas", PLoS Med5(4):e87.

31. David Fleming, Alice Albright (2008): "Advance Market Commitment for Pneumococcal disease: Innovative finance for development, GAVI Alliance

32. Department for International Development "How cost effective are the global health funds and partnerships?"

33. Department of Vaccines and Biologicals, WHO (2001): "Estimating the potential cost-effectiveness of using the Haemophilus Influenzae type b (Hib) vaccine - Field Trial Version I", World Health Organisation, Geneva

34. Devi Sridhar, Sanjeev Khagram, Tikki Pang (2008/2009): "Are existing governance structures equipped to deal with today's global health challenges - towards systematic coherence in scaling up", Global Health Governance Vol. II, No. 2

35. DFID (2009) : "How to note: Managing fiduciary risk when providing Financial Aid"

36. DFID (2009): "Statistics on international development 2004/05-2008/09"

37. Donald W. Light (2009): "Advance Market Commitments: Current realities and alternate approaches", Hai Europe, Medico International

38. ECA (2000): "Presentation: Country Financial Accountability Assessment (CFAA)with particular reference to ongoing work in Turkey", Prepared for the one day course on Public Expenditure Management, July 13, 2000 by Peter N. Dean, Principal Financial Management Specialist, ECA.

39. Ecotec Research and Consulting Ltd. (2003): "Evaluation of the added value and costs of the European Structural Funds in the UK", Department of Trade and Industry and the Office of the Deputy Prime Minister

40. Eliot T. Putnam Jr. (2009): "GAVI Alliance support for Civil Society Organisations – An analysis of Type A funding"

41. Florent Agueh, Santiago Cornejo, Judith Justice et al (2003): "Independent evaluation of the Global Alliance For the Elimination of Leprosy", GAEL

42. Francis Watkins: "Using Models of Partnership for Evaluation", PARC

43. Frost LJ and Reich MR. (2008). Access: How do good health technologies get into poor people in poor countries. 2008, Harvard Series on Population and International Health. ISBN 978-0-674-03215-6.

44. FT Cutts, SMA Zaman, G Enwere et al (2005): "Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial", Lancet;365:1139-46

45. GAVI (1999): "1st GAVI Board meeting minutes", October 1999

46. GAVI (2005): "16th GAVI Board – GAVI/VF Long-term supply strategy", Doc 9, July 2005

47. GAVI (2005): "16th GAVI Board Meeting minutes", 19-20 July 2005
48. GAVI (2006): "Final Summary Report, GAVI Alliance & Fund Board Meeting", 28–29 November 2006
49. GAVI (2007): "Final Summary Report, GAVI Alliance & Fund Board Meeting", 28–29 November 2007
50. GAVI (2007): "Workplan achievements within GAVI Alliance strategy 2007-10"
51. GAVI (2008): "Admin Budget 2009"
52. GAVI (2008): "Board Meeting minutes", 29–30 October 2008
53. GAVI (2008): "Board meeting minutes", July 2008
54. GAVI (2008): "Executive Committee meeting minutes", May 2008
55. GAVI (2008): "Executive Committee meeting minutes", Nov 2008
56. GAVI (2008): "GAVI Alliance 2009-10 Work Plan"
57. GAVI (2008): "Joint Board meeting minutes", Feb 2008
58. GAVI (2008): "Joint Board meeting minutes", Oct 2008
59. GAVI (2008): "Progress and achievements"
60. GAVI (2008): "Progress Report"
61. GAVI (2008): "Roadmap"
62. GAVI (2008): "Strategy (revised)", 29-30 October 2008
63. GAVI (2008): "Transparency and Accountability Policy"
64. GAVI (2009): "Board meeting minutes", Nov 2009
65. GAVI (2009): "Board Retreat meeting minutes", Mar 2009
66. GAVI (2009): "Executive Committee meeting minutes", April 2009
67. GAVI (2009): "Executive Committee meeting minutes", July 2009
68. GAVI (2009): "Executive Committee meeting minutes", Sept 2009
69. GAVI (2009): "Guidance Note: GAVI Financial Management Assessments"
70. GAVI (2009): "Update on co-financing policy", 30 September 2009
71. GAVI (2010): "Financial threat to global supply of vaccine puts 120 million at risk of yellow fever - Press release issued by the Yellow Fever Initiative", June 16, 2010.
72. GAVI (2010): "TAP Implementation", for Global Immunization Meeting, Geneva 1-3 February

73. GAVI Alliance & Fund joint EC meeting (2008): "AVI Update & ADIPs/ WHO budget extensions, Doc #AF.3, 6 May 2008

74. GAVI Alliance (2005): "16th GAVI Board - Supply Strategy for GAVI/VF Vaccines", Doc. 9, 6 Jul 2005, D Strombom

75. GAVI Alliance (2005): "Board Meeting minutes", New Delhi, 6–7 Dec 2005

76. GAVI Alliance (2005): "Evaluation of the progress of Yellow Fever control in Africa and the use of GAVI/VF support", 16th GAVI Board, Doc 18

77. GAVI Alliance (2005): "Revision and alignment of country support policies in Phase II: GAVI Alliance Delhi Board Meeting, 6–7 December 2005", Doc A.8

78. GAVI Alliance (2005): "Supply Strategy: GAVI Alliance Delhi Board Meeting, 6–7 December 2005", Doc AF.7

79. GAVI Alliance (2007): "Experiences of the GAVI Alliance Health System Strengthening Investment"

80. GAVI Alliance (2008): "Board Meeting minutes", 25–26 Jun 2008

81. GAVI Alliance (2008): "Executive Committee teleconference meeting minutes", 25 Nov 2008

82. GAVI Alliance (2008): "New Vaccine Co-Financing Policy Brief"

83. GAVI Alliance (2008): Update on the GAVI Alliance: Renewed Strategic Vision and Governance, PowerPoint presentation from the Vaccine Pre-Tender Meeting. UNICEF Supply, Copenhagen, December 10, 2008.

84. GAVI Alliance (2009): "Board Meeting minutes", 2-3 Jun 2009

85. GAVI Alliance (2009): "Board Meeting minutes", Mar 2009

86. GAVI Alliance (2010): "Board meeting minutes", 17–18 Nov 2010

87. GAVI Alliance and Fund Board Meeting (2010): "Vaccine Market Development", Doc # AF-9, 11–12 May 2007

88. GAVI Alliance and Fund Board meetings (2008): "GAVI financial support to the Advance Market Commitment (AMC) for Pneumococcal vaccines"

89. GAVI Alliance and Fund Joint EC meeting (2006): "The concept of Advance Market Commitments"

90. GAVI Alliance Board meeting (2008): "AMC update: For decision"

91. GAVI Alliance Board Meeting (2008): "Vaccine investment strategy", Doc #6, Oct 2008

92. GAVI Alliance Board Meeting (2009): "Advocacy and Communications Strategy: For Decision", Doc #3

93. GAVI Alliance Board meeting (2009): "Eligibility Policy: For decision"

94. GAVI Alliance Board meeting (2009): "Graduation Procedures: For decision"
95. GAVI Alliance EC electronic meeting (2007): "AMC start-up budget resubmission"
96. GAVI Alliance EC meeting (2009): "AMC offer agreement: For decision", Doc 1
97. GAVI Alliance EC meeting (2009): "Update on vaccine co-financing: For decision"
98. GAVI Alliance Investment Case (2006): "Accelerating the introduction of pneumococcal vaccines into GAVI-eligible countries", submitted by GAVI's PneumoADIP, Oct 2006
99. GAVI Alliance Programme and Policy Committee Meeting (2010): "Vaccine Supply Strategy", 17-18 Feb 2010, Doc 04
100. GAVI Alliance: "Financial sustainability for immunisation in the poorest countries: lessons from GAVI 2000-2006"
101. GAVI Alliance: "Findings of review of GAVI approved Health System Strengthening activities – Executive summary"
102. GAVI Board meetings (2005): "Progress report on IIFIm", Doc AF.6
103. GAVI Board teleconference (2004): "Final summary report"
104. GAVI Board teleconference (2004): "IIFIm – Final summary report"
105. GAVI Financing Task Force (2005): "Bridge Financing investment case"
106. GAVI Joint Executive Committee meeting (2007): "Work Plan update", 25 September 2007
107. GAVI Secretariat (2009): "Background note: Positive synergies paper and Lancet Editorial"
108. GAVI Secretariat: "AMC pilot proposal: AMC administration"
109. GAVI Secretariat: "GAVI Alliance new vaccine co-financing policy: Policy brief"
110. GAVI Website: "Media and Publications – GAVI in the news"
111. GAVI Website: "Media and Publications – Press releases"
112. GAVI: "16th GAVI Board - Update on the International Finance Facility for Immunisation", Doc. 19
113. GAVI: "Partner 2009 Workplan reporting"
114. GAVI: "Secretariat response: GAVI Phase I Evaluation"
115. GAVI: "Strategy 2008-10"
116. GAVI: "Workplan information/ Update 2009"

117. George Shakarishvili, Senior Advisor, HSS, The Global Fund (2009): "Exploring a potential common platform for funding and programming Health Systems Strengthening activities: An update on the Global Fund-World Bank-GAVI collaborative effort"

118. GFATM (2008): "Data Quality Audit Tool: Guidelines for implementation"

119. GFATM (2003): "Fiduciary Arrangements for Grant Recipients"

120. GFATM (2008): "The Global Fund Five-Year Evaluation - Country Selection Process"

121. GFATM (2009): "Performance based funding at the Global Fund"

122. GFATM (2010): "GFATM Third Replenishment: Trends in development assistance and domestic financing for health in implementing countries"

123. GFATM: "Income level and cost sharing eligibility criteria for proposals for funding from the Global Fund"

124. Gian Gandhi, Judith Kallenberg, Carol Marzetta et al: "Estimating the long range costs and impacts of investments by the GAVI Alliance in vaccines for the poorest countries around the world"

125. Giulia Greco et al (2008): "Countdown to 2015: Assessment of donor assistance to maternal, newborn and child health between 2003 and 2006", Lancet 2008; 371: 1268-75

126. Global HealthLink: "Following the money in global health"

127. Grace Chee et al (2008): "Evaluation of the GAVI Phase I performance (2000-2005)", Abt Associates Inc.

128. Harvard University, Institute for Health Metrics and Evaluation at the University of Washington, Johns Hopkins University, University of Queensland, World Health Organisation (2009): "GBD Study Operations Manual - Final Draft"

129. Hinman AR, Orenstein WA, Santoli JM, et.al. Vaccine Shortages: history, impact, and prospects for the future. Annu Rev Public Health (2006) 27:235–59.

130. HSLP (2009): "GAVI Health System Strengthening Support evaluation – Volume II", GAVI Alliance

131. IAVI Insights (2009): "Innovative Financing Mechanisms to Advance Global Health - Past, Present and Future Investments", International AIDS Vaccine Initiative

132. IIFIm (2006): "Report of the trustees and financial statements"

133. Independent Expert Committee Recommendation for AMC Pilot: "Executive Summary"

134. International Health Policy Program Thailand and Health Intervention and Technology Assessment Program (2008): "Research for development of an optimal policy strategy for prevention and control of cervical cancer in Thailand", Population and Reproductive Health Capacity Building Program, The World Bank.

135. Investment Case for Bridge Financing Update for GAVI Board; 2005.

136. Isabelle A. Rossi, Patrick L.F. Zuber, Laure Dumolard et al. (2007): "Introduction of Hib vaccine into national immunization programmes: A descriptive analysis of global trends", Vaccine 25(2007) 7075-7080

137. ITAD, HLSP (2008): "The Second Independent Evaluation of UNAIDS 2002-2008: Inception Report"

138. James P Watt, Lara J Wolfson, Katherine L O' Brien et al (2009): "Burden of disease caused by Haemophilus inlfuenzae type b in children younger than 5 years: global estimates", Lancet 2009;374:903-11

139. Jan M. Agosti, M.D., and Sue J. Goldie, M.D., M.P.H. (2007):"Introducing HPV Vaccine in Developing Countries - Key Challenges and Issues", NEJM 356;19 May 10 2007

140. Jean-Claude Berthelemy and Juliette Seban (2009): "Health expenditure and equity in access to health services in developing countries", Cairn

141. Jens Martens (2007): "Multistakeholder Partnerships - Future Models of Multilateralism?", Berlin Office of the Friedrich-Ebert-Stiftung

142. Johanna Hanefeld (2008): "How have global health initiatives impacted on health equity?", Promotion and Education 2008; 15;19, on behalf of International Union for Health Promotion and Education

143. John Grundy, Qiu Yi Khut, Sophal Oum et al. (2009): "Health system strengthening in Cambodia - A case study of health policy response to social transition", Health Policy

144. Jol Mitchell, Jill Shakleman, Michael Warner (2001): "Measuring the 'added-value' of tri-sector partnerships", Business Partners for Development, Natural resources Cluster, Working Paper No. 14

145. Joseph Naimoli (2009): "Global health partnerships in practice: taking stock of GAVI Alliance's new investment in health systems strengthening", International Journal of Health Planning and Management

146. Julian Gayfer, Juliet Pierce, Julia Flores, Achim Engelhardt (2004): "Global Funds and Partnerships - Literature review on the effectiveness of GFPs (2nd draft), PARC, Project no. 185

147. Kaddar M, Lydon P, Levine R. Financial challenges in immunisation: a look at GAVI. Bulletin of the World Health Organization (2004) 82: 697–702.

148. Kamara L, Milstien J, Patyna M, et al. (2008): “Strategies for financial stability of immunisation programs: a review of the strategies from 50 national immunisation program financial sustainability plans”, Vaccine (2008): 26 (51) 6716–26.

149. Karen Caines and Kent Buse, Cindy Carlson et al (2004): "Assessing the impact of global health partnerships", DFID Health Resource Centre

150. Ken Caplan, Joe Gomme, Josses Mugabi, Leda Stott (2007): "Assessing partnership performance: understanding the drivers for success", Building Partnerships for Development

151. Lancet Journal Article (2006): "Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment", Lu et al, Vol.368, 23 September, 2006

152. Lancet - Comment (2009): "What can be learned from data for financing of global health?", Lancet; 373

153. Lancet - Editorial (2009): "Who runs global health?", Lancet Vol. 373 June 20, 2009

154. Lancet - World Report (2009): "Dispute over Pneumococcal vaccine initiative", Lancet Vol. 374 December 5, 2009

155. Lancet Comment (2006): "Global health funding: A glass half full?", Lancet comment, Vol. 368, July 15, 2006

156. Lancet Comment (2009): "Sceptical optimism: a new take on global health data", Lancet;374

157. Lancet Comment (2009): "What can be learned from data for financing of global health?", Vol. 373, June 20, 2009

158. Lancet Comment (2010): "Are there simple conclusions on how to channel health funding",

159. Laura J Frost & Michael R. Reich (2008): "How do good health technologies get to poor people in poor countries?", Harvard Centre for Population and Development Studies

160. Laure Delcour, Charles Vellutini (2005): "Added value of global partnerships and global funds to development cooperation", IDC

161. Laurie Garrett (2007): "The challenge of global health", Council on Foreign Relations Inc.

162. Levin, Ann, David Pyle, Ousmane Dia, Marcia Rock, Ryan Callahan (2008): "*Evaluation of GAVI's Injection Safety Support",* Arlington, VA: JSI R&T

163. Lim SS, Stein DB, Charrow A, Murray CJL (2008): "Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertusssis immunisation coverage" , Lancet 2008; 372:2031–46

164. Logan Brenzel and Catriona Waddington "Health System Strengthening (HSS) Support from the GAVI Alliance: Early Experience and Lessons"

165. Long-term supply strategy document 9; 16th GAVI Board meeting, July 2005

166. Lydon P, Levine R, Mekinen M, et al. (2008): "Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability", Vaccine (2008) 26: 6706–6716"

167. Macro International Inc. (2008): "Evaluation of the Global Fund partner environment, at global and country levels, in relation to grant performance and health system effects, including 16 country studies - Final Report", The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva

168. Macro International Inc. (2009): "The Global Fund Five-Year Evaluation: Study Area 3 - The impact of collective efforts on the reduction of the disease burden of AIDS, Tuberculosis and Malaria", The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva

169. Madhi SA, Cunliffe NA, Steele D, Witte D, et.al. (2010): "Effect of human rotavirus vaccine on severe diarrhoea in African infants", NEJM; 362:289-98

170. Mahoney RT and Maynard JE. (1999): "The introduction of new vaccines in developing countries", Vaccine (1999) 17: 646–52

171. Manju Rani, BaopingYang, Richard Nesbit (2009): "Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications", Bulletin of the World Health Organisation 2009;87:707-713

172. Margaret Chan (2009): "Why the world needs global health initiatives", WHO

173. Marzetta CA, Wrobel SJ, Lorenson K, Landry S. (2010): "Retrospective analysis of vaccine uptake in GAVI-eligible countries", Abstract presented at International Global Health Conference, June 2010

174. Mathews, R. (2009): "Developments in UNICEF vaccine procurement", Global Immunisation Meeting, 17–19 February 2009, UNICEF Supply Division

175. Miller MA, Flanders WD. (2000): "A model to estimate the probability of hepatitis B- and Haemophilus influenzae type b-vaccine uptake into national vaccination programs", Vaccine (2000)18:2223–2230

176. Milstien J, Cohen JC, Olsen IT. (2007): "An evaluation of the GAVI Alliance efforts to introduce new vaccines via the Accelerated Development and Introduction Plans (ADIPs) and the Hib Initiative", HSLP, February 2007

177. Milstien J, Kamara L, Lydon P, et al. (2008): "The GAVI financing task force: one model of partner collaboration", Vaccine (2008) 26: 6699–6705

178. Monath T, Cetron M, Teuwen D. Yellow Fever Vaccine. Vaccines, 5th Edition, Saunders Elsevier, 2008.

179. Monitoring and Evaluation Working Group of the International Health Partnership and Related Initiatives (IHP+): "Monitoring performance and and evaluating progress in the scale-up for better health - A proposed common framework"

180. Moran M, et al. (2005): "Executive summary for the new landscape of neglected diseases drug development, London School of Economics and Wellcome Trust

181. Munira SL and Fritzen SA. What influences government adoption of vaccine in developing countries? A policy process analysis. Social Sci & Med (2007) 65:1571-1764

182. Nancy Birdsall et al (2010): "Cash on delivery: A new approach to foreign aid", Centre for Global Development

183. Nel Druce, Anjali Gopalan, Melinda Moree et al (2009): "Evaluation of the International AIDS Vaccine Initiative 2003-2007", IAVI

184. Nicole A. Szlezak, Barry R. Bloom, Dean T. Jamison et al (2010): "The global health system: actors, norms, and expectations in transition", PLoS Medicine Vol 7, Issue 1

185. Nirmala Ravishankar, Paul Gubbins, Rebecca J Cooley et al (2009): "Financing of global health: tracking development assistance for health from 1990 to 2007 – Supplementary web annex"

186. OECD (2007): "Global Forum on Development – Policy workshop on the challenges of scaling up at country level: Predictable aid linked to results"

187. OECD Development Assistance Committee (2008): "Report of 2008 survey of aid allocation policies and indicative forward spending plans"

188. Oya Celasun, Jan Walliser (2007): "Predictability of aid: Do fickle donors undermine economic development?", 46th Panel Meeting of Economic Policy in Lisbon October 19-20, 2007

189. P. Lydon, R. levine, M. Makinen, L. Brenzel et al (2008): "Introducing new vaccines in the poorest countries: What did we learn from the GAVI experience with financial sustainability?", Vaccine 26, 6706-6716

190. Paris, France: Document

191. PATH (2009): "Strategies and stories from the field"

192. Paul Farmer, Laurie Garrett (2007): "From "Marvellous Momentum" to health care for all: Success is possible with the right programs", Council on Foreign Affairs, Inc.

193. Pearman J. Briefing Session: AVI Overview. GAVI Partners Forum, Hanoi, Vietnam, 18 November 2009

194. Peter C Smith (2009): "Measuring value for money in healthcare: concepts and tools", Quest for Quality and Improved Performance

195. Peter Hill, Naima Hammani et al (2007): "Key features of the 2006-2007 proposals: a report to the GAVI HSS task team – Preliminary findings from the first 31 proposals"

196. Philippe Beutels, Nancy Thiry, Pierre Van Damme (2006): "Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006)", Vaccine 25(2007) 1355-1367

197. Programme Coordinating Board, UNAIDS (2002): "Five-Year Evaluation of UNAIDS", UNAIDS/PCB(13)/02.2

198. Ravishankar, et al. Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet (2009)

199. Regien G Biesma, Ruairi Brugha, Andrew Harmer et al (2009): "The effects of global health initiatives on country health systems: a review of the evidence from HIV/AIDS control", Health policy and Planning, 24;239-252

200. Rena Eichler, Ruth Levine and the Performance-Based Incentives Working Group (2009): "Performance incentives for global health – Potential and pitfalls", Centre for Global Development, Washington D.C.

201. Revision of GAVI's Vaccine Supply Strategy: Proposed Project Plan, Doc. 04, Programme and Policy Committee Meeting, 17–18 February 2010

202. Roll Back Malaria (2005): "A Global Advocacy Framework to Roll Back Malaria 2006-2015"

203. Rosenbom, KA. (2010): "Developments in UNICEF Vaccine Procurement: Immunisation in the Context of Global Interdependence", Global Immunisation Meeting, 3 February 2010. UNICEF Supply Division

204. Rotavirus Vaccine Program (2006): " Accelerating the Introduction of Rotavirus Vaccines into GAVI-Eligible Countries", GAVI

205. Ruth Levine (2004): "Tracking resources for global health: progress towards a policy-responsive system", Centre for Global Development

206. Ruth Levine (2009): "Wedding bells for GAVI, the World Bank and the Global Fund?", Global Health policy

207. Ryoh Sasaki (2006): "A review of the history and the current practice of aid evaluation", Journal of Multi-Disciplinary Evaluation, No. 5

208. Sarah Thomson, Tom Foubister, Josep Figueras, Joseph Kutzin, Govin Permanand, Lucie Bryndova ((2009): "Addressing financial sustainability in health systems", WHO on behalf of the European Observatory on Health Systems and Policies

209. Severine Deneulin and Nicholas Townsend (2006): "Public goods, global public goods and the common good", ESRC Research Group on Wellbeing in Developing Countries, WeD Working Paper No. 18

210. Shaun K Morris, William J Moss, Neal Halsey (2008): "Haemophilus influenzae type b conjugate vaccine use and effectiveness", Lancet Vol 8;435-443

211. Shearer JC, et al.: Accelerating Policy Decisions to Adopt Haemophilus B influenza Type B Vaccine: A Global, Multivariable Analysis, PLoS Medicine (2010) 7(3):e1000249

212. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet (2007) 369:389-96.

213. Solomon R Benatar (2008/2009): "Global health: Where to now?", Global Health Governance, Volume II, No. 2

214. Stephen S. Lim et al (2008): "Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus and pertussis immunisation coverage"

215. Strategic Demand Forecast History 2003–2008. PneumoADIP, 2009.

216. Sue J. Goldie, Meredith O'Shea, Nicole G. Campos et al (2008): "Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries", Vaccine 26 (2008) 4080-4093

217. Swiss Centre for International Health (2010): "GAVI consultancy services for AMC baseline study: Draft report"

218. Tania Cernuschi (2010): "The pilot Advance Market Commitment for vaccines", GAVI Alliance

219. The Henry J. Kaiser Family Foundation (2009): "The U.S. Global Health Initiative Budget Analysis"

220. The Hib initiative Newsletter Vol. 4, No. 2, August 2009

221. The Vaccine Provision Project: Lessons Learned from the Pilot Phase, July 2002 – October 2003, Draft Report to the GAVI Board, 2003

222. Tim Nielander (2008): "AMC update", GAVI Alliance Board meeting

223. Timothy Powell-Jackson et al (2006): "Tracking donor assistance to maternal, newborn and child health", Lancet 2006; 368: 1077-87

224. U.S. Global Health policy (2009): "The U.S. Global Health Initiative: Overview and budget analysis"

225. Ulla K. Griffiths (2008): "Co-financing of new and underused vaccines supported by GAVI: Information collected during the June 2008 review of 41 Annual Progress Reports"

226. UNDP (2005): "Framework for cash transfers to implementing partners"

227. UNICEF (2003): "Supply Division Annual Report"

228. UNICEF (2008): “Supply Annual Report 2008: Global Availability, Local Delivery”

229. UNICEF (2009): “Bank report”

230. UNITAID: “Strategy 2010-12”

231. USAID (2009): “Sustaining health gains – Building systems: Health systems report to Congress”, USAID, Washington D.C.

232. US GAO (1999): “Factors Contributing to Low Vaccination Rates in Developing Countries”, Oct 1999

233. Walsh J and Mitu A.: “The Critical Path for Vaccine Introduction: An Analysis Based upon the Rapid Introduction of Rotavirus Vaccines into Mexico and Brazil”

234. Wayne Pisano: "Leveraging Partnerships"

235. WB (2003): “Country Financial Accountability Assessment Guidelines to Staff”

236. WB (2010): “Partner Work Plan Report: 18-19 May 2010”

237. Weekly Epidemiological Record (2003) 78(14):97–120

238. Weekly Epidemiological Record (2003) 78(40):349-360

239. Weekly Epidemiological Record (2004) 79(28):253–264

240. Weekly Epidemiological Record (2007) 82(12):93–104

241. Weekly Epidemiological Record (2007) 82(32):285–296

242. Weekly Epidemiological Record (2009) 84(40):405–420

243. Weekly Epidemiological Record (2009) 84(51–52):533–540

244. Weekly Epidemiological Record, WHO. 11 February 2005; 80 (6) 50–55

245. WHO (1993): “Expanded Program on Immunization: Program report for the year 1992”

246. WHO (1998): “Yellow Fever”, WHO/EPI/GEN/98.11

247. WHO (2007): “Vaccine Introduction Guidelines: Adding a vaccine to a national immunisation program: decision and implementation”, WHO/IVB/05.18

248. WHO (2008): “Trends in comprehensive Multi Year Planning”, Global Immunisation meeting 2008

249. WHO (2009): "Public health, innovation and intellectual property: Role of the Expert Working Group on research and development financing", Executive Board, 126th Session, Provisional agenda item 4.3

250. WHO (2009): Initial summary conclusions - Maximising positive synergies between health systems and Global Health Initiatives

251. WHO (2010): “Partner Work Plan Report: 18-19 May 2010”

252. WHO (2010): “Yellow Fever Initiative, Providing an opportunity of a lifetime”

253. WHO Maximizing Positive Synergies Collaborative Group (2009): "An assessment of interactions between global health initiatives and country health systems", Lancet;373:2137-69

254. WHO, UNICEF (2005): “GIVS (Global Immunization Vision and Strategy) 2006-2015”

255. WHO, UNICEF (2008): “Eliminating serogroup A meningococcal meningitis epidemics as a public health problem in Africa, an investment case for the GAVI Alliance”

256. WHO, UNICEF, World Bank (2009): "State of the world's vaccines and immunization, 3rd ed.", Geneva, World Health Organisation

257. Wilson P. (2010): “Giving developing countries the best shot: An overview of vaccine access and R&D”, Oxfam International

258. Yellow Fever Initiative (2008): “Investment Case, Continuation Proposal”, Submitted to the GAVI Alliance, May 2008

259. Yellow Fever Task Force (2005): “Yellow Fever Stockpile Investment Case”, Submitted to GAVI

260. Yellow Fever Task Force (2010): “Yellow Fever Stockpile Investment Case”, Submitted to GAVI

1.2. GAVI documents – confidential

GAVI Evaluations

1. Axios International, Macro International (2008): "Consultancy services for conducting a monitoring and evaluability study for GAVI's Health System Support to countries"
2. Euro Health Group, Liverpool Associates in Tropical Health (2004): "Redefining GAVI Hib strategy: The country consultation process – Summary Report"
3. Euro Health Group, Liverpool Associates in Tropical Health (2006): "Independent Review of GAVI 2004-2005 Work Plan – Final Report"
4. GAVI (2003): "Achieving our immunisation goal – Final Report"
5. GAVI (2004): "Strengthening GAVI's governance process and structures in the context of convergence – 2004 Governance Review Final Report", 14th GAVI Board Meetings, 4-5 December 2004, Abuja, Nigeria
6. GAVI (2008): "Advance Market Commitment for Pneumococcal vaccines – Report of the monitoring and evaluability study"
7. GAVI (2008): "GAVI's added value as a Public Private Partnership"
8. GAVI (2009): "HSS Database – Final"
9. GAVI (2009): Terms of Reference for 2012 Evaluation"
10. GAVI Alliance and Fund Board Meeting (2007): "Evaluation of the ADIPs and Hib Initiative"
11. GAVI Alliance Secretariat: "Organisational Review"
12. GAVI: "Enhancing GAVI's Public Private Partnership Model – Executive Summary"
13. GAVI: "ISS Evaluation: Follow up on recommendations"
14. HLSP (2005): "Lessons learned from GAVI Phase I and design of Phase II: Findings of the country consultation process"
15. HLSP (2010); "Review of GAVI Independent Review Committees (IRCs)"
16. HSS Task Team (2009): "Lessons learned"
17. J. Patrick Vaughan (2006): "Self assessment of core and expanded core activities, priority setting, expenditures and estimated unfunded mandate of the multilateral partners"
18. Javier Martinez (2008): "Review of the Health Systems Support (HSS) component of Annual Progress Reports submitted to the GAVI Alliance in 2008", HLSP
19. JSI Evaluation Planning Team (2008): "Monitoring and evaluation study for the GAVI Alliance support for CSOs – Final report and proposed monitoring and evaluation plan", JSI Research and Training Institute, Inc.

20. Judith Kallenberg (2008): "Evaluation of the Accelerated Development and Introduction Plans (ADIPs) and the Hib Initiative Summary, recommendations and follow up", GAVI Secretariat

21. Julie Milstien, Jillian Clare Cohen, Ingvar Theo Olsen (2007): "An evaluation of GAVI Alliance efforts to introduce new vaccines via the Accelerated Development and Introduction Plans (ADIPs) and the Hib Initiative (HI)", HLSP

22. Karen Caines, Hatib N'jie (2002): "Report of the external review of the functions and interactions of the GAVI working group, Secretariat and Board"

23. Martin Donoghue, Mark Watson (2005): "Lessons learned from the investment case approach", HLSP

24. McKinsey and Company: "Strengthening technical support – GAVI Alliance"

25. Mercer (2002): "Lessons learned: New procurement strategies for vaccines – Final Report to the GAVI Board"

26. Monitor Company Group, L.P. (2008): "Organisational assessment and recommendations"

27. Nel Druce, Martin Donoghue, Cheri Grace, Veronica Walford (2006): "Immunisation: mapping the bigger picture – Final Report to GAVI Roles and Responsibilities Task Team", HLSP

28. Saatchi & Saatchi Simko (2005): "Report and recommendations on development and implementation of a brand strategy and corporate identity for GAVI and the Vaccine Fund"

29. The Boston Consulting Group (2005): "Global vaccine supply: the changing role of suppliers – External Stakeholder Advisory Board Meeting", GAVI

30. WHO (2009): "Comment on the Health Systems Strengthening Evaluation conducted by HLSP"

31. Wolfgang Weber, Xavier Bosch-Capblanch (2009): "Consultancy services for conducting an evaluation of immunisation coverage and monitoring methodology and process – Interview component", Swiss Centre for International Health

32. Xavier Bosch-Capblanch, Barbara Matthys, Carine Weiss (2009): "Consultancy services for conducting an evaluation of immunisation coverage and monitoring methodology and process – Literature Review component", Swiss Centre for International Health

33. Xavier Bosch-Capblanch, Carine Weiss (2009): "Consultancy services for conducting an evaluation of immunisation coverage and monitoring methodology and process – Statistical component", Swiss Centre for International Health

GAVI Progress Reports

34. GAVI (2006): "Work Plan Technical and Financial Report"
35. GAVI Alliance World Bank Trust Fund: "Report for the period January 1 to December 31, 2008"
36. GAVI: "2007 Work Plan achievements within the GAVI Alliance 2007-10 Strategy"
37. GAVI: "2008 Progress Report Narrative"
38. GAVI: "Media Report : GAVI at the World Economic Forum 2010 Media Report"
39. GAVI: "Trust Fund Work Plan 2009"
40. UNICEF (2009): "Technical Progress Report: UNICEF contribution to the Implementation of the GAVI Work Plan over the period January – December 2008"
41. WHO (2009): "WHO End of Year Implementation Report on the 2008 GAVI Work Plan"
42. WHO (2009): "WHO's contribution to the achievement of the 2008 GAVI HSS Task Team Work Plan"
43. WHO: "GAVI 2008 HCWM/ 72 countries"

Strategy Documents

44. GAVI (2009): "GAVI Strategy 2011-15: Mission, Strategic objectives and KPIs – Consultation Interviews"
45. GAVI (2009): "Semi-structured interview guide with board members/constituencies strategy development"
46. GAVI (2010): 'Investing in immunisation through the GAVI Alliance – The evidence base'
47. GAVI (2010): "Communications, Advocacy & Resource Mobilisation (CARM) Directions 2010-2011: Framework Document"
48. GAVI Work Plans / Budgets for 2003-2010
49. GAVI: "CARM Roadmap 2010"
50. GAVI: "Draft interview guide responses + schedule"

Other documents

51. GAVI (2010): "GAVI 2010-12 Events Calendar"
52. GAVI (2010): "Impact of IFFIm-funded investment cases"
53. GAVI Alliance (2009): "Monitoring Framework and Plan – Draft"

54. GAVI Alliance: "Letter to MOH Ethiopia – Global eligibility for Rotavirus vaccine"
55. GAVI Performance Based Financing Task Team: "Description of the Advisory Group"
56. Vaccine Presentation and Packaging Advisory Group (2008): "Revised Terms of Reference"
57. WHO (2009): "Introduction of rotavirus vaccines into national immunisation programmes – Management manual including operational information for health workers"
58. Work Plan Review Committee (2008): "WPVC recommendations on 2009-2010 Work Plan activities"